楚天科技股份有限公司 投资者关系活动记录表 编号：2025-009 | | □特定对象调研 □分析师会议 | | --- | --- | | 媒体采访 调研活动类别 | 业绩说明会 | | | □新闻发布会 □路演活动 | | 现场参观 | □其他 | | 参与单位名称 | 投资者网上提问 | | 及人员姓名 | | | 时 间 2025 | 年 9 月 19 日 14:30-17:00 | | 地 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | 点 | 采用网络远程的方式召开业绩说明会 | | 上市公司接待 | 董事会秘书：黄玉婷 | | 人员姓名 | 证券事务代表：周德伟 | | 问题 | 1、你好！请问公司年度扭亏为盈的目标能不能完成？ | | | 您好！公司在《2024 年年度报告》中披露了 2025 年的经营目标为 | | | 实现年度扭亏为盈，截至 2025 年上半年，公司综合毛利率持续提升， | | | 严控各项费用及成本。2025 年上半年亏损同比大幅收窄，公司将持 | | | 续进行管理优化、巩固国内市场、加大国际市场开拓、加强产品开 | | ...

Group 1: Company Overview - Chutian Technology Co., Ltd. is a well-known supplier of intelligent pharmaceutical equipment and overall technical solutions, focusing on various fields including chemical drugs, raw materials, biological drugs, and traditional Chinese medicine [2] - The company has expanded into the medical beauty and cosmetics sectors as part of its development strategy [2] Group 2: Financial Performance - The company aims to achieve profitability in 2025 after a loss in the first quarter, with expectations to turn around by mid-year or the third quarter through improved operational efficiency [2] - In 2024, Romaco Group reported a revenue of €208.75 million, a 1.26% increase year-on-year, but a net profit decline of 91.08% [4] Group 3: Order and Revenue Recognition - Domestic main engine orders are recognized upon obtaining customer-signed installation acceptance certificates, while international orders are recognized upon obtaining customs declarations and bills of lading [3] - The manufacturing cycle for main products typically ranges from 3 to 9 months, with delivery influenced by customer site conditions and project progress [2] Group 4: Impact of Tariffs - The impact of U.S. tariffs on sales is minimal, as exports to the U.S. account for a very small portion of overall revenue [3] - The company has reduced reliance on direct imports from the U.S. by developing core components in-house and utilizing domestic or alternative imported brands [3] Group 5: International Market Expansion - The company has established localized sales and service networks in over 10 key countries and regions, enhancing its international competitiveness [5] - In 2024, domestic exports exceeded 1.2 billion, with products entering high-end markets in Europe [6] Group 6: New Products and Business Development - The company has made significant progress in the fields of peptides, medical beauty, and blood products, establishing a smart factory for beauty products [6] - Chutian Technology has set up a joint venture in peptide synthesis, with total assets of approximately ¥15.61 million and a net loss of ¥2.22 million in 2024 [6]

Group 1: Industry Trends - The global pharmaceutical equipment market has surpassed $50 billion in 2024 and is expected to exceed $80 billion by 2030, with a compound annual growth rate (CAGR) of approximately 6-8% [1] - The "14th Five-Year" Pharmaceutical Industry Development Plan supports the development of high-end pharmaceutical equipment, with "domestic substitution" becoming a market trend [1] - The demand for equipment is rapidly increasing due to the transformation and upgrading of the pharmaceutical industry, driven by the rise of innovative drugs, biopharmaceuticals, and personalized formulations [2] Group 2: Technological Advancements - The construction of smart pharmaceutical factories is accelerating, with the adoption of MES systems, SCADA systems, and intelligent robots [2] - Data traceability has become a core element of GMP compliance, necessitating automated recording, audit trails, and electronic signatures [2] - The National Medical Products Administration's draft for the revised Good Manufacturing Practice (GMP) for sterile drugs aims to enhance the quality of sterile drug production in China [2] Group 3: Market Dynamics - There is a rising demand for personalized, small-batch, and multi-variety production, particularly for oncology drugs and rare disease medications [2] - Chinese pharmaceutical equipment companies are increasingly achieving international quality standards, enabling them to compete with top global firms [3] - The Asia-Pacific region, especially China and India, along with Latin America and the Middle East, is becoming a new growth driver for the global pharmaceutical equipment market [3] Group 4: Company Performance and Strategy - The increase in contract liabilities is attributed to a rise in orders and corresponding prepayments, without significant changes to the company's credit policy [3] - The company aims to enhance its international market presence and improve the quality of domestic contracts to drive business growth [3] - The company is focused on cost reduction and efficiency improvement through product optimization, supply chain cost management, and enhanced production efficiency [3] Group 5: Financial Overview - As of December 31, 2024, Chutian Microbead reported total assets of ¥81,528,093.58, net assets of ¥44,136,789.35, revenue of ¥14,738,069.68, and net profit of ¥635,992.39 [4] - Chutian Siwei Kang reported total assets of ¥24,429,337.66, net assets of ¥18,291,639.27, revenue of ¥9,688,180.16, and net profit of ¥5,529,069.30 as of December 31, 2024 [4] - Chutian Siyoute reported total assets of ¥32,086,926.74, net assets of -¥38,928,231.79, revenue of ¥7,933,943.61, and a net loss of -¥22,328,736.00 as of December 31, 2024 [4]